Literature DB >> 11192935

Paracetamol-inhibitable COX-2.

R Botting1.   

Abstract

Although paracetamol potently reduces pain and fever, its mechanism of action has so far not been satisfactorily explained. It inhibits both COX-1 and COX-2 weakly in vitro, but reduces prostaglandin synthesis markedly in vivo. In mouse macrophage J774.2 cells, COX-2 induced for 48 hr with high concentrations of NSAIDs is more sensitive to inhibition with paracetamol than endotoxin-induced COX-2. In the rat pleurisy model of inflammation, a second peak of COX-2 protein appears 48 hr after administration of the inflammatory stimulus, during the resolution phase of the inflammatory process. Inhibition of the activity of this late-appearing COX-2 with indomethacin or a selective COX-2 inhibitor, delays resolution and the inflammation is prolonged. Cultured lung fibroblasts also express COX-2 activity after stimulation with IL-1beta which is highly sensitive to inhibition with paracetamol. Thus, evidence is accumulating for the existence of a COX-2 variant or a new COX enzyme which can be inhibited with paracetamol.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11192935

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  3 in total

Review 1.  Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?

Authors:  Timothy D Warner; Jane A Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

2.  Comparison of the effects of acetaminophen to ketorolac when added to lidocaine for intravenous regional anesthesia.

Authors:  Myoung Jin Ko; Jeong Han Lee; Soon Ho Cheong; Chee Mahn Shin; Young Jae Kim; Young Kyun Choe; Kun Moo Lee; Se Hun Lim; Young Hwan Kim; Kwang Rae Cho; Sang Eun Lee
Journal:  Korean J Anesthesiol       Date:  2010-04-28

Review 3.  Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.

Authors:  C J Hawkey; M J S Langman
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.